Hansa Biopharma AB (HNSBF) Stock

About Hansa Biopharma AB

Hansa Biopharma AB (publ), a biopharmaceutical company, engages in development and commercialization of treatments for patients with rare immunological conditions in Sweden, North America, and rest of Europe. The company offers Idefirix(imlifidase), which targets and cleaves all classes of immunoglobulin G (IgG) antibodies for the desensitization treatment of sensitized adult kidney transplant patients with a positive crossmatch test. It is also developing HNSA-5487, a next generation IgG-cleaving enzyme to address acute and chronic neuro-autoimmune conditions, including myasthenia gravis. In addition, the company evaluates imlifidase in three therapy areas, including autoimmune, gene therapy, and transplantation. It has a collaboration agreement with Sarepta Therapeutics to assess imlifidase as a pre-treatment in limb-girdle muscular dystrophy (LGMD) and duchenne muscular dystrophy (DMD); AskBio to evaluate imlifidase as a pre-treatment in pompe disease; and research and development collaboration agreement with Genethon to evaluate the safety and efficacy of imlifidase as pre-treatment to gene therapy in Crigler-Najjar syndrome patients with anti-AAV antibodies. Hansa Biopharma AB (publ) was incorporated in 2007 and is headquartered in Lund, Sweden.

Hansa Biopharma AB is headquartered in SE.

Hansa Biopharma AB (HNSBF) stock trades at $2.90 with a market capitalization of $289.23M. The stock is valued at a price-to-earnings (P/E) ratio of -4.72, price-to-book of -7.25, price-to-sales of 19.51. Over the past 52 weeks the stock has ranged between $2.73 and $4.58, and currently trades 36.7% below its 52-week high.

On profitability, Hansa Biopharma AB generates a return on equity (ROE) of 213.16% — well above the market average, a sign of a high-quality business, return on capital employed of -114.06%, an operating margin of -310.89%, a net profit margin of -406.50%.

Official website: www.hansabiopharma.com